Podcasts about apple app store

We asked you to give advice to a Maid of Honor who isn't sure if she should be in the wedding, Chunky Dunking had us chuckling ducklings so we needed to hear your family's made up phrases, and Whip's anti-summer Hot Take is so hot it's cold! Catch up on everything you missed from today's show on The Morning Mix Podcast!Listen to The Morning Mix weekdays from 5:30am - 10:00am on 101.9fm The Mix in Chicago or with the free Mix App available in the Apple App Store and Google Play.Follow The Mix: The MixstagramGet the Free MIX App: Stream The MixSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

God's in control. He showed that He's in control of history by His prophecies and use of a heathen king, Cyrus, and He's also in control of your life and mine. The challenge of this message is to consider our ways. Are we striving against God's purposes, talking back to the Potter and saying “He can't with me” or, “What could I possibly do?” Or are we looking at the pattern of God's way with Cyrus and saying, “Lord, Thy will be done. If You accomplished Your purposes with Cyrus, a heathen king, You can do the same with me.”   VF-1999 Isaiah 44:27-28, Isaiah 45:1-12 Watch, Listen and Learn 24x7 at PastorMelissaScott.com Pastor Melissa Scott teaches from Faith Center in Glendale. Call 1-800-338-3030 24x7 to leave a message for Pastor Scott. You may make reservations to attend a live service, leave a prayer request or make a commitment. Pastor Scott appreciates messages and reads them often during live broadcasts. Follow @Pastor_Scott on Twitter and visit her official Facebook page @Pastor.M.Scott. Download Pastor Scott's "Understand the Bible" app for iPhone, iPad and iPod at the Apple App Store and for Android devices in the Google Store. Pastor Scott can also be seen 24x7 on Roku and Amazon Fire on the "Understand the Bible?" channel. ©2025 Pastor Melissa Scott, Ph.D., All Rights Reserved

Cheating is bad but almost cheating hurts more sometimes, you or your partner get waaaaayyy to into you rec league sports team, and today's Mix & Match fails so hard it's a big win! Catch up on everything you missed from today's show on The Morning Mix Podcast!Listen to The Morning Mix weekdays from 5:30am - 10:00am on 101.9fm The Mix in Chicago or with the free Mix App available in the Apple App Store and Google Play.Follow The Mix: The MixstagramGet the Free MIX App: Stream The MixSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Zerubbabel, one born in Babylon, was an unlikely person to return to Jerusalem to rebuild; yet he did.  He was chosen by God not only to rebuild but also to preserve the bloodline to Christ.  No matter what circumstance you are born into, if God calls you, you are part of His plan. VF-1998 Haggai 2:20-23 Watch, Listen and Learn 24x7 at PastorMelissaScott.com Pastor Melissa Scott teaches from Faith Center in Glendale. Call 1-800-338-3030 24x7 to leave a message for Pastor Scott. You may make reservations to attend a live service, leave a prayer request or make a commitment. Pastor Scott appreciates messages and reads them often during live broadcasts. Follow @Pastor_Scott on Twitter and visit her official Facebook page @Pastor.M.Scott. Download Pastor Scott's "Understand the Bible" app for iPhone, iPad and iPod at the Apple App Store and for Android devices in the Google Store. Pastor Scott can also be seen 24x7 on Roku and Amazon Fire on the "Understand the Bible?" channel. ©2025 Pastor Melissa Scott, Ph.D., All Rights Reserved

A clip went viral on TikTok of a woman making crashing a wedding and making a speech so we heard about the crazy things you saw at a wedding, we run the gamut on today's Weekend Oopsie, and people have numbers so close to other popular numbers they get misdialed all the time...sometimes 5 times a day! Catch up on everything you missed from today's show on The Morning Mix Podcast!Listen to The Morning Mix weekdays from 5:30am - 10:00am on 101.9fm The Mix in Chicago or with the free Mix App available in the Apple App Store and Google Play.Follow The Mix: The MixstagramGet the Free MIX App: Stream The MixSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

When it comes to the work we are called to do for God, in frustration some may ask, “What's the point?” Nothing God calls us to do is small in His eyes. It counts to Him. We are to be diligent and faithful in the smallest things for God, like the vigilant gatekeepers, the singers that were the spiritual vitality and the Levites (the minutia men). VF-1997 Nehemiah 7:1-4 Watch, Listen and Learn 24x7 at PastorMelissaScott.com Pastor Melissa Scott teaches from Faith Center in Glendale. Call 1-800-338-3030 24x7 to leave a message for Pastor Scott. You may make reservations to attend a live service, leave a prayer request or make a commitment. Pastor Scott appreciates messages and reads them often during live broadcasts. Follow @Pastor_Scott on Twitter and visit her official Facebook page @Pastor.M.Scott. Download Pastor Scott's "Understand the Bible" app for iPhone, iPad and iPod at the Apple App Store and for Android devices in the Google Store. Pastor Scott can also be seen 24x7 on Roku and Amazon Fire on the "Understand the Bible?" channel. ©2025 Pastor Melissa Scott, Ph.D., All Rights Reserved

Cancellations will always happen — but there's a way to reduce and prevent them from happening! In this episode, Kirk Behrendt brings back Miranda Beeson, ACT's director of education, to break down cancellation and no-show percentage and what you can do if you have high levels of broken appointments. Stop making it too easy to cancel! To learn the secret to getting patients to show up, listen to Episode 919 of The Best Practices Show!Learn More About Miranda:Send Miranda an email: miranda@actdental.com Follow Miranda on ACT's Instagram: https://www.instagram.com/actdentalSend Courtney an email to learn more about ACT: courtney@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast: https://podcasts.apple.com/us/podcast/the-best-practices-show-with-kirk-behrendt/id1223838218Episode Resources:Watch the video version of Episode 919: https://www.youtube.com/@actdental/videosRegister for ACT's To The Top Study Club (July 25, 2025): https://www.eventbrite.com/e/climb-with-us-register-for-july-25-2025-ttt-study-club-tickets-1205497959849Main Takeaways:Your ideal cancellation/no-show percentage is under 10%.Proactively reach out to patients with unconfirmed appointments.Put a system in place for releasing or keeping unconfirmed appointments.Have a reminder system that utilizes both automated and personal outreach.Be intentional with your language. Don't call to confirm appointments — remind them.Communicate the value of appointments to patients and policies around missed visits.Snippets:0:00 Introduction.3:15 Cancellation and no-show percentage, explained.5:16 How this percentage impacts the practice.7:59 What it looks like when it's going well.9:47 What it looks like when it's not going...

The FIYAH SHOW, hosted by Yielded, airs on the Anointed Radio Network every Tuesday from 4 p.m. to 7 p.m. (Central Standard Time). The FIYAH SHOW provides a platform for humor, inspiration, and uplifting conversations. It's a space where the Word of God meets everyday life, with the motto: Where Real Talk Sparks Real Change and the slogan: Putting a Lil Heat to da Word on the Street.  Download the Anointed Radio Network App from the Google Play or Apple App Store to tune in live. ⁠www.anointedradio.com/⁠ Social Media: YouTube: @ibeYielded Instagram: @ibeYielded Facebook: @YieldedMedia Business Inquiries Email: ⁠yieldedmedia@gmail.com⁠ Watch us on Roku TV via the Anointed Radio Network Channel. Support this show: ⁠https://linktr.ee/yieldedmedia⁠ #FIYAHSHOW #RealTalkRealChange #PuttingALilHeat #AnointedRadio #ibeyielded #GospelEntertainment #ChristianTalkShow #HumorAndInspiration

Award-Winning Anointed Radio Network is a Las Vegas ChristianRadio Station provides a platform for all Christians to come and share about their businesses or talents. The Anointed Radio Motto is that (It is time to unite) every Wednesday 6 pm-7 pm (Pacific Standard Time (PST)Download the Anointed Radio Network App from the Google Play or Apple App Store.www.anointedradio.com/Social Media: Twitter:@lvanointedradio Instagram:@lvanointedradio Facebook:@ Anointed Radio Business inquires email: Lvanointedradio@gmail.com

Message by: Patrick Ballington. The Bridge Church is located at 607 Hulsey Road, Cleveland Georgia. The church that "Connects Faith and Life". Download our app by searching "The Bridge Church, Cleveland and Apple App Store or GooglePlay Store. Bridge Streams live Sundays @ 9:00 and 11:00 am. Streaming under CCLI License Number #CSPL072350

A couple got caught allegedly cheating at the Coldplay concert on Wednesday so we needed to know about the times you got caught out and we let you decide which song Chris Martin could have sung during the awkward moment (Shaggy It Wasn't Me Anyone?). Catch up on everything you missed from today's show on The Morning Mix Podcast!Listen to The Morning Mix weekdays from 5:30am - 10:00am on 101.9fm The Mix in Chicago or with the free Mix App available in the Apple App Store and Google Play.Follow The Mix: The MixstagramGet the Free MIX App: Stream The MixSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Despite the quality of his character, Nehemiah was under constant attack by enemies. They used the tricks of the devil: sending emissaries from hell or close by, egregious lies, entrapment, and emotional sabotage, but that did not deter Nehemiah from the work God sent him to do. We face the same tactics of opposition in building God's church today, but if we keep our hands to the plow, God will get the victory. VF-1996 Nehemiah 6 Watch, Listen and Learn 24x7 at PastorMelissaScott.com Pastor Melissa Scott teaches from Faith Center in Glendale. Call 1-800-338-3030 24x7 to leave a message for Pastor Scott. You may make reservations to attend a live service, leave a prayer request or make a commitment. Pastor Scott appreciates messages and reads them often during live broadcasts. Follow @Pastor_Scott on Twitter and visit her official Facebook page @Pastor.M.Scott. Download Pastor Scott's "Understand the Bible" app for iPhone, iPad and iPod at the Apple App Store and for Android devices in the Google Store. Pastor Scott can also be seen 24x7 on Roku and Amazon Fire on the "Understand the Bible?" channel. ©2025 Pastor Melissa Scott, Ph.D., All Rights Reserved

You might think you're great at multitasking — but you're really not! In this episode, Kirk Behrendt brings in Renae Graeff, one of ACT's amazing coaches, to share how to maximize your dental assistants' skills so you can fully utilize them to better your practice. Don't try to do it all! To learn how to empower your assistants so they become more capable, more fulfilled, and a better partner for patient care, listen to Episode 918 of The Best Practices Show!Learn More About Renae:Send Renae an email: renae@actdental.com Follow Renae on ACT's Instagram: https://www.instagram.com/actdentalSend Courtney an email to learn more about ACT: courtney@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast: https://podcasts.apple.com/us/podcast/the-best-practices-show-with-kirk-behrendt/id1223838218Episode Resources:Watch the video version of Episode 918: https://www.youtube.com/@actdental/videosRegister for ACT's To The Top Study Club (July 18th, 2025): https://www.eventbrite.com/e/climb-with-us-register-for-july-18-2025-ttt-study-club-tickets-1205460116659Register for ACT's To The Top Study Club (July 25, 2025): https://www.eventbrite.com/e/climb-with-us-register-for-july-25-2025-ttt-study-club-tickets-1205497959849Register to ACT's BPA for their 3-3-3 Onboarding Tool: https://join.actdental.com/users/sign_in?post_login_redirect=https%3A%2F%2Fjoin.actdental.com%2Fc%2Fpractice-coaching-tools%2F3-3-3-onboarding-model#emailRegister to ACT's BPA for their...

Over 5,000 women in Ireland intentionally set the record for most people skinny dipping so we wanted to hear about your accidental nakedness, Bill Burr dissed Chicago so today's Thursday Threestyle is a Boston takedown, and more people are repairing than buying new so we had to know what your latest YouTube repair was. Catch up on everything you missed from today's show on The Morning Mix Podcast!Listen to The Morning Mix weekdays from 5:30am - 10:00am on 101.9fm The Mix in Chicago or with the free Mix App available in the Apple App Store and Google Play.Follow The Mix: The MixstagramGet the Free MIX App: Stream The MixSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Nehemiah lived and walked with an awareness of God's presence and a healthy fear of God. We can take a page out of his instruction, which will help us to depart from evil and to break free of the things that have bound us. VF-1994 Nehemiah 5:9, Nehemiah 5:15 Watch, Listen and Learn 24x7 at PastorMelissaScott.com Pastor Melissa Scott teaches from Faith Center in Glendale. Call 1-800-338-3030 24x7 to leave a message for Pastor Scott. You may make reservations to attend a live service, leave a prayer request or make a commitment. Pastor Scott appreciates messages and reads them often during live broadcasts. Follow @Pastor_Scott on Twitter and visit her official Facebook page @Pastor.M.Scott. Download Pastor Scott's "Understand the Bible" app for iPhone, iPad and iPod at the Apple App Store and for Android devices in the Google Store. Pastor Scott can also be seen 24x7 on Roku and Amazon Fire on the "Understand the Bible?" channel. ©2025 Pastor Melissa Scott, Ph.D., All Rights Reserved

Dani Pinter (Senior Vice President at the NCOSE Law Center) and Haley McNamara (Senior Vice President at NCOSE) react to the latest update to Grok which include chatbot avatars that can act as your companion – even as a romantic connection. “Ani” is depicted as a very young anime girl who is programmed to be “crazy in love” with the user and can have progressively more sexually explicit interactions as the user advances through the conversation. This even includes getting the bot to describe itself as a young child or to play along with sexual fantasies with a child-like motif. All of this is available before activating “spicy mode.” This is obviously quite disturbing for a number of reasons, but even more upsetting is the access that kids have to this tool with no meaningful age verification in place to protect minors. Also, the Apple App Store has assigned this app as appropriate for ages 12 and up.   TAKE ACTION Contact Apple: https://advocacy.charityengine.net/Default.aspx?isid=2608 Sign the Petition for changes to Grok: https://advocacy.charityengine.net/Default.aspx?isid=2609   FURTHER READINGRead our full blog about the Grok AI companion: https://endsexualexploitation.org/articles/xais-12-chatbot-designed-to-be-explicit-and-go-full-literotica/ Read Thorn's article about hashing: https://www.thorn.org/blog/hashing-detect-child-sex-abuse-imagery/ Read The Guardian article about AI-Generated CSAM: https://www.theguardian.com/technology/2025/jul/10/ai-generated-child-sexual-abuse-videos-surging-online-iwf   Follow Dani Pinter on X: https://x.com/DaniBPinter Follow Haley McNamara on X: https://x.com/HaleyMcNamara  

Dr. Joshua Reuss joints that podcast to discuss the latest changes to the living guideline on stage IV NSCLC with driver alterations. He discusses the new evidence for NSCLC with EGFR mutations and NRG1 fusions and how this impacts the latest recommendations from the panel. He shares ongoing research that the panel will review in the future for further updates to this living guideline, and puts the updated recommendations into context for clinicians treating patients with stage IV NSCLC. Read the full living guideline update “Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1” at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-01061 Brittany Harvey: Hello and welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Joshua Reuss from Georgetown University, co-chair on "Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1." It's great to have you here today, Dr. Reuss. Dr. Joshua Reuss: Thank you. Happy to be here. Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Reuss, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So to dive into what we're here today to talk about, Dr. Reuss, this living clinical practice guideline for systemic therapy for patients with stage IV non–small cell lung cancer with driver alterations is updated on an ongoing basis. So what prompted this latest update to the recommendations? Dr. Joshua Reuss: Yes, thank you. It's very important that we have living guidelines that are continuously updated. We obviously don't live in a static environment where things are non-changing, and we really need to apply the most up-to-date and current evidence to treat our patients with the most effective strategies, the most groundbreaking strategies. And so to have guidelines that can be disseminated, particularly these ASCO guidelines, to treating providers is incredibly important. So, with any of these updates, we review ongoing studies, published work, for the quality of evidence to see if it's something that warrants making adjustments to our guidelines or at least incorporating the information so that providers can review it and incorporate this into their own personal decision-making. So in this particular update, we reviewed evidence particularly pertaining to EGFR-mutated non–small cell lung cancer and non–small cell lung cancer harboring an NRG1 fusion. Brittany Harvey: Yes, certainly there's a lot of new evidence in the advanced non–small cell lung cancer field, and so we appreciate the panel's continuous review of this evidence. So then you just mentioned two separate areas where the panel reviewed new evidence. So starting with that first one, what updated evidence did the panel review on first-line treatment options for patients with EGFR alterations, and how did this impact the recommendations? Dr. Joshua Reuss: Yes, so advanced EGFR-mutated non–small cell lung cancer, at least with classical activating alterations - that is our exon 19 deletions and our exon 21 L858R mutations - is something that's really evolved rapidly in the last few years. You know, for many years, we basically, for the frontline treatment setting, were saying, "Okay, we have a targeted therapy, osimertinib. We're going to give that, and we're going to see what effect we can get out of that," with, you know, a median time of duration of treatment response averaging around 18 months, knowing that there are some that that's a lot longer and some that are a lot shorter. But recently, we've seen a lot of data emerging on combination strategies. The guideline has already been updated to incorporate two of these combinations: osimertinib with chemotherapy based off of the FLAURA2 trial, and then the combination of amivantamab with lazertinib based off of the MARIPOSA trial. And that was data on progression-free survival that was published and led to those particular recommendations. Now, more recently, we've seen data come out in smaller, randomized studies for other combinations. And more recently, we reviewed the RAMOSE study. So this was a phase II, open-label, randomized trial for patients with tyrosine kinase inhibitor–naive and really, treatment-naive advanced EGFR-mutated non–small cell lung cancer harboring one of these two classical EGFR alterations, randomized to either osimertinib alone or osimertinib with the combination of ramucirumab, which is an anti-VEGF agent. There's been a lot of data, preclinical and clinical, for the role of VEGF blockade, particularly in EGFR-mutated non–small cell lung cancer, so exploring the combination of this for synergy in the frontline setting really made a lot of sense. So again, this was a phase II trial that randomized patients prospectively to one of these two regimens. The population here is really what we typically see with EGFR-mutated non–small cell lung cancer, predominantly a younger population - median age on this study was 65 - predominantly female - 71% female - and predominantly nonsmokers. Now, what this study showed was that at a median follow-up of 16.6 months, the progression-free survival favored the combination arm with a median progression-free survival of 24.8 months with the combination of osimertinib plus ramucirumab versus 15.6 months for osimertinib alone, for a hazard ratio of benefit of 0.55. The landmark one- and two-year endpoints for progression-free survival also favored the combination arm, and response rates were relatively comparable between groups, with overall adverse events being more frequent in the combination group, specifically high blood pressure, proteinuria, and epistaxis, which are our common adverse events related to VEGF-blocking agents. So, it's good to see data in this space. Now, of note, though, this was a phase II study, so not a phase III level of evidence. In addition, when looking at the population, this was a randomized, multicenter study, but it was a US-only population. There was also some imbalance in the number of visits between arms, so the combination arm was seen more frequently than the arm that got osimertinib alone. Now, the imaging assessments were no different, but obviously this could lead to potential confounding, at least in timing of awareness of potential side effects and and things being brought to the attention of investigators. So very promising data here, but because, you know, of this being a phase II study, this actually led to no changes in the guideline at this time. Brittany Harvey: Understood. Yes, as you mentioned prior, it's important to understand the full body of evidence and to review the trials even when it doesn't impact the recommendations. Dr. Joshua Reuss: And I will say that, you know, there is an ongoing phase III study looking at a very similar combination. It's the phase III ECOG-ACRIN trial of the combination of osimertinib plus bevacizumab versus osimertinib alone in this specific population. So, you know, I think we will see phase III–level data for a combination of VEGF with osimertinib, but again, promising phase II data that did not lead to a change in the recommendation at this time. Brittany Harvey: Absolutely. We'll look forward to that ongoing trial to learn more about combination in this patient population. So then moving to that second patient population that you mentioned earlier where the panel reviewed evidence, what is the updated evidence and recommendation for patients with NRG1 fusions? Dr. Joshua Reuss: Yeah, so this was an exciting update that we made more recently with this unique iteration of the living guidelines. So, NRG1 fusions, this is perhaps a newer kid on the block in terms of driver alterations that has been known to be identified in non–small cell lung cancer among other solid tumors. It is very rare, occurring in less than 1% of solid tumors, but something that we know is a unique oncogenic pathway that can lead to oncogenesis and cancer development, including in non–small cell lung cancer. So up until now, unfortunately, there have not been targeted therapies that target this unique alteration. It's somewhat different than other driver alterations where there's a top-level signaling change in a protein. This is more of a ligand alteration that then alters, that then enables activation of more classical pathways, but again, through upregulation of a unique ligand. So a slightly different pathway but something that we know should be able to be targeted to promote patient survival for those with NRG1 fusions. So the therapy here is a therapy called zenocutuzumab. It's an IgG1 bispecific antibody against HER2 and HER3. So it prevents the downstream dimerization and signaling that occurs as a result of this NRG1 fusion and upregulation of the NRG1 signal. This was, as you can imagine with a rare alteration, a large phase II registrational study that examined this in advanced solid tumors containing the NRG1 fusion. This is the NRG1 registrational trial. And this study enrolled patients with advanced solid tumors who had progressed on prior therapy. Patients were treated with zenocutuzumab 750 milligrams IV every two weeks. Among 158 response-evaluable solid tumor patients, the response rate was 30%, median duration of response of 11.1 months, and a median progression-free survival of 6.8 months. Now, in those with non–small cell lung cancer, that made up 93 response-evaluable patients, very similar outcomes there: a response rate of 29%, median duration of response of 12.7 months, and a median progression-free survival of 6.8 months. This therapy did appear to be well tolerated. The most common higher-grade emergent side effects - grade 3 or higher - were anemia occurring in 5% and elevated liver numbers occurring in 3%. So this is a subsequent-line study, so this led to the updated recommendation that clinicians may offer zenocutuzumab in the subsequent-line setting for patients with advanced non–small cell lung cancer who harbor NRG1 fusions. So I think this does speak toward the incredible importance of next-generation sequencing and molecular testing for patients, particularly to include testing that looks at the RNA. These large fusions can sometimes be very challenging to detect on DNA sequencing platforms alone, so it's important to, if you have a high level of suspicion for an alteration like this, perhaps some of the mucinous adenocarcinomas where it's been challenging to find a driver alteration, and it's someone who is a never-smoker, really would want to include molecular testing that assesses the RNA level and not just the DNA. Brittany Harvey: Absolutely. It's important to have all the biomarkers available so that clinicians are able to use that to inform their decision-making. So then, given these changes in the guideline, what should clinicians know as they implement this latest living guideline update? And how do these changes impact patients? Dr. Joshua Reuss: Yeah, I think talking in reverse order of what we just discussed here, there is a new guideline update for NRG1 fusions. So I think making sure that that's being evaluated, that clinicians are testing for that and really looking for that result that should be incorporated in in most next-generation large sequencing assays to get that result, but it's very important that that is not overlooked now that we do have a therapy that's available in the subsequent-line setting, though it is important to note that patients with NRG1 fusions, at least the limited data that there is suggests that the efficacy to standard chemoimmunotherapy regimens is overall poor. So physicians unfortunately might be facing this question for second-line therapy in patients with NRG1 fusions sooner rather than later. For the former, for EGFR-altered non–small cell lung cancer and how do we incorporate VEGF-containing regimens into these patients? Our guideline top-level update did not change based off of review of this new study, but it's important for clinicians to know what other combinations may exist. You know, there are phase III studies looking at this combination in the frontline setting. And of course, there is data on other bispecific molecules that incorporate VEGF in the subsequent-line setting, particularly a combination that includes the VEGF/PD-1 bispecific antibody ivonescimab that's being studied in the HARMONi-A trial for patients with EGFR-mutated advanced non–small cell lung cancer, for which we hope to get some more definitive data in the coming months. Brittany Harvey: Definitely. And then you've just mentioned a few ongoing trials where we're looking for evidence to inform future updates. But thinking beyond that, into the future, what is the panel examining for future updates to this living guideline? Dr. Joshua Reuss: It's a very exciting time to be in the world of treating advanced non–small cell lung cancer, particularly patients with driver alterations, because there is so much evolving data that's changing our practice in real time, again highlighting the importance of these living guideline updates. I'd say there's many things that we're excited to see. You know, a lot of the combination regimens in EGFR-mutated non–small cell lung cancer for which there are approvals and current recommendations in our guideline, particularly osimertinib plus chemotherapy and amivantamab plus lazertinib - those are the two approved combination strategies in the front line - we are now seeing the emergence of overall survival data for those combinations. So obviously that is something that's going to be very important for the committee to review and incorporate into guideline updates. There are several new therapies coming down the road for other driver populations. We recently saw an approval for taletrectinib for ROS1 fusion–positive non–small cell lung cancer, so it's going to be important that the committee reviews the data and the publications regarding that therapy. And then there are other novel therapies that we're looking to see updated data on. There are multiple antibody-drug conjugates, which take the potent power of a chemotherapy molecule and attempt to make that targeted with an antibody targeting to a unique feature on the cancer cell. And there are several antibody-drug conjugates that are in development at various levels of promise in this space, particularly in EGFR-mutated non–small cell lung cancer, and I anticipate seeing some emerging data for that coming up in the near future as well. So really, lots to be excited in the space and lots for our committee to review to give guidance on so that these patients can really receive the top-level care wherever they are being treated in the country and throughout the world. Brittany Harvey: Yes, we'll await this new data to continue to provide optimal options for patients with stage IV non–small cell lung cancer with driver alterations. So, Dr. Reuss, I want to thank you so much for your work to rapidly and continuously update and review the evidence for this guideline and thank you for your time today. Dr. Joshua Reuss: Thank you so much. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines Podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available on the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Dr. Lyudmila Bazhenova is back on the podcast to discuss the latest update of the living guideline on therapy for stage IV NSCLC without driver alterations. She shares the studies the Expert Panel reviewed in the first- and second-line settings, including NIPPON, HARMONi-2, and DUBLIN-3. Although these studies do not impact the existing guideline recommendations, Dr. Bazhenova provides context and comments on ongoing trials that will influence the next iteration of the living guideline. Read the full living guideline update “Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1” at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-01062 Brittany Harvey: Hello, and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Lyudmila Bazhenova from University of California San Diego Moores Cancer Center, co-chair on "Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1." It's great to have you back on the show today, Dr Bazhenova. Dr. Lyudmila Bazhenova: It's my pleasure to be here. Brittany Harvey: And then before we discuss this guideline update, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Bazhenova, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into the content here, Dr. Bazhenova, this living clinical practice guideline for systemic therapy for patients with stage IV non–small cell lung cancer without driver alterations is updated on an ongoing continuous basis. So what prompted this latest update to the recommendations? Dr. Lyudmila Bazhenova: Living ASCO guidelines are designed to keep pace with rapidly evolving evidence that impacts treatment of our patients with lung cancer. As a committee, we are tasked with regular review of the published literature and determine if the new data warrants changes to existing recommendations. So in this recently published update, we evaluated new trials related to treatment of patients with metastatic lung cancer without driver alterations. Brittany Harvey: Excellent. Thank you for that explanation of the process. So, you just mentioned that the panel reviewed new trials for this update. So, which particular updated evidence did the panel review on first-line treatment options for patients with good performance status across histology and PD-L1 expression status, and how did this impact the recommendations? Dr. Lyudmila Bazhenova: For the first-line treatment option for patients without driver alterations, two studies met our criteria for review. One was the NIPPON trial from Japan, the second was the HARMONi trial. None of those two trials resulted in change in our guidelines, but I think they are giving us some additional information that would be useful for the way we treat patients with non–small cell lung cancer without driver alterations. For example, if we take those patients, we currently have several treatment options as a first line. One is monotherapy immunotherapy. You can give pembrolizumab as an example, and that was based on the KEYNOTE-024 and KEYNOTE-042 trials. Then we have a platinum doublet plus immunotherapy, and there are several trials that did that pathway. And then we have also an option of giving our patients dual IO immunotherapy combination, such as CheckMate 9LA and POSEIDON. At this point, we do not have any randomized trials comparing those three treatment modalities head-to-head. And the NIPPON trial was interesting to us because it was the first trial to compare CheckMate 9LA regimen, which is again, dual immunotherapy plus chemo, versus KEYNOTE-189 or KEYNOTE-407, which is a chemotherapy plus immunotherapy. And as a result of the study, while chemotherapy plus ipilimumab-nivolumab led to numerically higher overall survival, the difference was not statistically significant. And what is concerning in that trial is that we saw a higher number of treatment-related death occurring in nivolumab and ipilimumab arm compared to the pembrolizumab-chemotherapy arm. As a matter of fact, the trial was terminated early because of the increased risk of death. If you look at the treatment-related death in CheckMate 9LA, the 9LA study reported the treatment-related death to be 2%, and then in the NIPPON trial, the treatment-related death was 7%. Why is that happening? It's really difficult to say. The study was done in Japan. Maybe there is some pharmacogenomic differences between global population and Japan population. But certainly the higher rate of adverse events needs to be taken into account. Another interesting thing about this trial is that it did not show any differences in a subset analysis for patients with squamous histology as well as PD-L1 negative tumor. So while this does not change our current guidelines and CheckMate 9LA treatment still remains an appropriate treatment option, it kind of raises the possibility that this combination could be associated with a higher toxicity. And we do have a randomized US-based trial that is ongoing, and we are hoping that eventually we will be able to answer that question after the trial will be completed. The second trial we reviewed is HARMONi-2. So HARMONi-2 was a randomized, double-blind study which is conducted primarily in China, looking at bispecific PD-L1 and VEGF antibody called ivonescimab. And that took patients who were PD-L1 positive, as defined as more than 1% expression, and patients were randomized to pembrolizumab versus bispecific ivonescimab. And the study was positive. It showed improvement in median progression-free survival of 11 months versus almost 6 months in bispecific versus pembrolizumab. There were, however, higher grade 3 events in the ivonescimab arm. At this point, we are not changing our recommendations because this trial was done in an ex-US population, and we are awaiting a similar trial ongoing in the United States before we change recommendations and decide if ivonescimab needs to be included in our guidelines. Brittany Harvey: This context is very helpful when clinicians think through the data behind these options. And it's important that the panel reviews this evidence, even if it doesn't prompt a change to the recommendations. And we'll await results of those trials that you mentioned to further inform this guideline. So then beyond those studies for first line, what updated evidence did the panel review for second-line and subsequent treatment options for patients with good performance status, and how did this impact the recommendations? Dr. Lyudmila Bazhenova: So for second line, only one trial met the criteria, and that was DUBLIN-3. DUBLIN-3 is a phase 3 single-blind randomized trial comparing docetaxel versus docetaxel plus plinabulin. And the study enrolled patients with second or third line. They have to have had platinum-based chemotherapy and progressed. Plinabulin is an interesting compound. It's a small molecule tubulin binder that prevents polymerization of tubulin and appears to impact dendritic cell maturation and T-cell activation. This study enrolled 559 patients, randomly assigned them to two groups. And one important information about this study is that was a study that was envisioned before immunotherapy became a standard mainstream treatment for first-line therapy. And only 20% of patients had prior PD-1 exposure. So therefore, the results of that study need to be taken into context of this population no longer existing in the United States because we use PD-L1 inhibitors in the first line. And we saw that interesting in the plinabulin arm had lower rates of neutropenia but higher rates of serious adverse events. And at this point, we are not changing our guidelines for mainly two reasons. Number one, low number of patients that received prior treatment with first-line immune checkpoint inhibitors, as well as a modest overall survival benefit of this trial. Brittany Harvey: Understood. I appreciate you describing that study as well and why that evidence didn't prompt a change to those particular recommendations. So then, what should clinicians know as they implement this living guideline, and how does this new evidence impact clinicians and patients? Dr. Lyudmila Bazhenova: At this point, none of the studies that we reviewed resulted in a change in guidelines. We are still waiting for more global results from some of the studies that I highlighted. It shows that there's still a lot of questions we need to be answering in those patients. And I'm hoping that with future clinical trials, we will be able to definitively maybe recommend one treatment over another. But at this point, all the treatments that I mentioned before remain appropriate for patients with stage IV non–small cell lung cancer without driver alterations. Brittany Harvey: Definitely. And then you just mentioned that there's still a lot of outstanding questions in this field. You've mentioned a couple different studies where we're awaiting evidence. Beyond those that you already mentioned, what is the panel examining for future updates to this living guideline? Dr. Lyudmila Bazhenova: Right now, our next task is to come up with a full guidelines update. ASCO have certain rules for the guidelines committee members. And so we are gearing for a full guideline update, which hopefully will be ready by the end of 2025. Brittany Harvey: Excellent. We'll look forward to that full update of the living guideline, and we'll still await results of these ongoing trials to further inform this living guideline. So I want to thank you so much for your work to rapidly and continuously update this living guideline, and thank you for the time today, Dr. Bazhenova. Dr. Lyudmila Bazhenova: My pleasure. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you've enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Do you think about what you want your life to look like when you grow up? So did an Irish poet long ago, and the hymn that came from their poem challenges many people to put God first. U-Nite TV Uniting kids with the God's Word in a fun, engaging way to help kids understand and apply biblical truths to their lives. Stream animated adventures, music videos, missionary stories, and more! Available on Android, iOS, Android TV, and Apple TV. https://www.cefonline.com/unitetv/ U-Nite Kids App Uniting kids in with God's Word to help them grow in their faith through personal devotions. Play adventures that teach truths from the Bible, complete daily devotions, earn achievements, memorize God's Word, and get answers to common biblical questions. Available on the Apple Appstore, Google Play, and the Amazon Appstore. https://www.cefonline.com/unitekids/ Copyright © 2025 Child Evangelism Fellowship Inc. All rights reserved. Scripture quotations are from the ESV® Bible (The Holy Bible, English Standard Version®), copyright© 2001 by Crossway, a publishing ministry of Good News Publishers. Used by permission. All rights reserved.

Be careful what your order (or don't order) from the internet, Whip delivers a scalding hot baggage take, and your fashion injuries included falling out of flip flops and getting knocked out with minion goggles on. Plus, we get a special call from WGN's (and friend of the show) Sarah Jindra! Catch up on everything you missed from today's show on The Morning Mix Podcast!Listen to The Morning Mix weekdays from 5:30am - 10:00am on 101.9fm The Mix in Chicago or with the free Mix App available in the Apple App Store and Google Play.Follow The Mix: The MixstagramGet the Free MIX App: Stream The MixSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Adversity, discouragement and disappointment will either drive you away from, or make you run to God.  When we run out of our own strength, God gives His strength.  The cure for discouragement: Prepare, Prayer, Perseverance, Power (of memory), Protection, and Praise.  Let's build. VF-1993 Nehemiah 4:10 Watch, Listen and Learn 24x7 at PastorMelissaScott.com Pastor Melissa Scott teaches from Faith Center in Glendale. Call 1-800-338-3030 24x7 to leave a message for Pastor Scott. You may make reservations to attend a live service, leave a prayer request or make a commitment. Pastor Scott appreciates messages and reads them often during live broadcasts. Follow @Pastor_Scott on Twitter and visit her official Facebook page @Pastor.M.Scott. Download Pastor Scott's "Understand the Bible" app for iPhone, iPad and iPod at the Apple App Store and for Android devices in the Google Store. Pastor Scott can also be seen 24x7 on Roku and Amazon Fire on the "Understand the Bible?" channel. ©2025 Pastor Melissa Scott, Ph.D., All Rights Reserved

How you communicate will make or break your practice. In this episode, Kirk Behrendt brings back Miranda Beeson, ACT's director of education, to break down the DiSC framework to help you better understand yourself and your team so you can improve communication and harmony in your practice. To take the first step to optimize your leadership style, listen to Episode 917 of The Best Practices Show!Learn More About Miranda:Send Miranda an email: miranda@actdental.com Follow Miranda on ACT's Instagram: https://www.instagram.com/actdentalSend Courtney an email to learn more about ACT: courtney@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast: https://podcasts.apple.com/us/podcast/the-best-practices-show-with-kirk-behrendt/id1223838218Episode Resources:Watch the video version of Episode 917: https://www.youtube.com/@actdental/videosRegister for ACT's To The Top Study Club (July 18th, 2025): https://www.eventbrite.com/e/climb-with-us-register-for-july-18-2025-ttt-study-club-tickets-1205460116659Register for ACT's To The Top Study Club (July 25, 2025): https://www.eventbrite.com/e/climb-with-us-register-for-july-25-2025-ttt-study-club-tickets-1205497959849Register for ACT's Guide to Engaging Your Team with Data: https://join.actdental.com/users/sign_in?post_login_redirect=https%3A%2F%2Fjoin.actdental.com%2Fc%2Fpractice-coaching-tools%2Fguide-to-engaging-your-team-with-data#emailMain...

PDA can be cute but most of the time it's gross so we wanted to know the weirdest places you saw people getting after it, we mix and matched the show's dream statues, and by 38 you should have mastered a skill...that's why a 13 year old called into put us all to shame. Catch up on everything you missed from today's show on The Morning Mix Podcast!Listen to The Morning Mix weekdays from 5:30am - 10:00am on 101.9fm The Mix in Chicago or with the free Mix App available in the Apple App Store and Google Play.Follow The Mix: The MixstagramGet the Free MIX App: Stream The MixSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

"The Gospel in the Gates:" a visual tour through the gates of Jerusalem studying the meaning of the names of the gates and the people who built them. VF-1992 Nehemiah 3 Watch, Listen and Learn 24x7 at PastorMelissaScott.com Pastor Melissa Scott teaches from Faith Center in Glendale. Call 1-800-338-3030 24x7 to leave a message for Pastor Scott. You may make reservations to attend a live service, leave a prayer request or make a commitment. Pastor Scott appreciates messages and reads them often during live broadcasts. Follow @Pastor_Scott on Twitter and visit her official Facebook page @Pastor.M.Scott. Download Pastor Scott's "Understand the Bible" app for iPhone, iPad and iPod at the Apple App Store and for Android devices in the Google Store. Pastor Scott can also be seen 24x7 on Roku and Amazon Fire on the "Understand the Bible?" channel. ©2025 Pastor Melissa Scott, Ph.D., All Rights Reserved

Lots of people have goals to write a book so we wanted to know what you would title your memoir, Bill gave us the best tip on how to diffuse any argument with your partner, and Bono hated his hair during U2's Live Aid performance so we wanted to hear your Big Day Fails. Plus! Someone added The Mix to their family group chat and then called us to talk about why! Catch up on everything you missed from today's show on The Morning Mix Podcast!Listen to The Morning Mix weekdays from 5:30am - 10:00am on 101.9fm The Mix in Chicago or with the free Mix App available in the Apple App Store and Google Play.Follow The Mix: The MixstagramGet the Free MIX App: Stream The MixSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Nehemiah had a concern for God's work and His people, a calling to rebuild, and the confidence in God's will to be done.  We face the same challenges today that Nehemiah faced, and our attitude should be the same as his.  When we pull together in faith to rebuild, the Lord will hear our prayers, instruct, and sustain us. VF-1991 Nehemiah 2:10-20 Watch, Listen and Learn 24x7 at PastorMelissaScott.com Pastor Melissa Scott teaches from Faith Center in Glendale. Call 1-800-338-3030 24x7 to leave a message for Pastor Scott. You may make reservations to attend a live service, leave a prayer request or make a commitment. Pastor Scott appreciates messages and reads them often during live broadcasts. Follow @Pastor_Scott on Twitter and visit her official Facebook page @Pastor.M.Scott. Download Pastor Scott's "Understand the Bible" app for iPhone, iPad and iPod at the Apple App Store and for Android devices in the Google Store. Pastor Scott can also be seen 24x7 on Roku and Amazon Fire on the "Understand the Bible?" channel. ©2025 Pastor Melissa Scott, Ph.D., All Rights Reserved

Cancellations and no-shows will always happen. But how well are you filling those gaps? In this episode of Metric Mondays, Kirk Behrendt brings back Miranda Beeson, ACT's director of education, to break down capacity percentage. They share the keys to maintaining a productive and efficient schedule even when your patients fall out. Don't settle for 84%! To learn how to proactively fill your schedule, listen to Episode 916 of The Best Practices Show!Learn More About Miranda:Send Miranda an email: miranda@actdental.com Follow Miranda on ACT's Instagram: https://www.instagram.com/actdentalSend Courtney an email to learn more about ACT: courtney@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast: https://podcasts.apple.com/us/podcast/the-best-practices-show-with-kirk-behrendt/id1223838218Episode Resources:Watch the video version of Episode 916: https://www.youtube.com/@actdental/videosRegister for ACT's To The Top Study Club (July 18th, 2025): https://www.eventbrite.com/e/climb-with-us-register-for-july-18-2025-ttt-study-club-tickets-1205460116659Register for ACT's To The Top Study Club (July 25, 2025): https://www.eventbrite.com/e/climb-with-us-register-for-july-25-2025-ttt-study-club-tickets-1205497959849Main Takeaways:Your capacity percentage benchmark is 94% or higher.Pre-schedule your patients' next appointments before they leave.Utilize ideal day or block scheduling. Protect your high-value time blocks.Have someone own and review your schedule two days to two weeks in advance.When you have cancellations and no-shows, quickly fill those gaps using priority lists.Utilize...

We all have favorite snacks, drinks, and fast food treats that we love. However, every so often, those treats get discontinued for some reason or other. As a fond remembrance of foods past, Geek Salad is bringing you episode 257: The FDA's Secret Restricted Warehouse of Lost Foods. Join Andy, Mike, Joe, and Katherine (as well as the participators in their live stream) as they go over some of their favorite tasty treats of ages past. From Wendy's baked potato bar to Jolt Cola, they go over some of the items which satisfied their taste buds but have since been consigned to that big walk-in freezer in the sky. Did they unearth some fond memories for you? Geek Salad is available at www.geeksalad.podbean.com, or can be subscribed to at the iTunes store by using keyword “geek salad.”  Geek Salad is also available on Spotify,iTunes,  iHeart Radio and wherever else you get your podcasts! Also, check out the Podbean App where you can stream and download the entire Geek Salad archive right from your Android or iPhone!  You can get the app at either the Google Play Store or the Apple App Store!  Want Geek Salad swag?  Check out our new store on Tee Public, where you can get t-shirts, mugs, stickers, and so much other stuff!!!  Shop here! Geek Salad episodes are now also available to stream on YouTube.  “Like” and Subscribe to their channel at Geek Salad Podcast at www.youtube.com Contact Geek Salad at geeksaladradio@gmail.com.  Geek Salad is also available on Facebook under the group heading “Geek Salad Podcast.” Check out their website at www.geek-salad.com, and please subscribe to their Twitter/X, Threads, and Blue Sky feeds: @geeksaladradio Geek Salad is intended for adult listeners and contains coarse language and profanity.  Listener discretion is advised.

The FIYAH SHOW, hosted by Yielded, airs on the Anointed Radio Network every Tuesday from 4 p.m. to 7 p.m. (Central Standard Time). The FIYAH SHOW provides a platform for humor, inspiration, and uplifting conversations. It's a space where the Word of God meets everyday life, with the motto: Where Real Talk Sparks Real Change and the slogan: Putting a Lil Heat to da Word on the Street.  Download the Anointed Radio Network App from the Google Play or Apple App Store to tune in live. ⁠www.anointedradio.com/⁠ Social Media: YouTube: @ibeYielded Instagram: @ibeYielded Facebook: @YieldedMedia Business Inquiries Email: ⁠yieldedmedia@gmail.com⁠ Watch us on Roku TV via the Anointed Radio Network Channel. Support this show: ⁠https://linktr.ee/yieldedmedia⁠ #FIYAHSHOW #RealTalkRealChange #PuttingALilHeat #AnointedRadio #ibeyielded #GospelEntertainment #ChristianTalkShow #HumorAndInspiration

The FIYAH SHOW, hosted by Yielded, airs on the Anointed Radio Network every Tuesday from 4 p.m. to 7 p.m. (Central Standard Time). The FIYAH SHOW provides a platform for humor, inspiration, and uplifting conversations. It's a space where the Word of God meets everyday life, with the motto: Where Real Talk Sparks Real Change and the slogan: Putting a Lil Heat to da Word on the Street.  Download the Anointed Radio Network App from the Google Play or Apple App Store to tune in live. ⁠www.anointedradio.com/⁠ Social Media: YouTube: @ibeYielded Instagram: @ibeYielded Facebook: @YieldedMedia Business Inquiries Email: ⁠yieldedmedia@gmail.com⁠ Watch us on Roku TV via the Anointed Radio Network Channel. Support this show: ⁠https://linktr.ee/yieldedmedia⁠ #FIYAHSHOW #RealTalkRealChange #PuttingALilHeat #AnointedRadio #ibeyielded #GospelEntertainment #ChristianTalkShow #HumorAndInspiration

Award-Winning Anointed Radio Network is a Las Vegas ChristianRadio Station provides a platform for all Christians to come and share about their businesses or talents. The Anointed Radio Motto is that (It is time to unite) every Wednesday 6 pm-7 pm (Pacific Standard Time (PST)Download the Anointed Radio Network App from the Google Play or Apple App Store.www.anointedradio.com/Social Media: Twitter:@lvanointedradio Instagram:@lvanointedradio Facebook:@ Anointed Radio Business inquires email: Lvanointedradio@gmail.com

The FIYAH SHOW, hosted by Yielded, airs on the Anointed Radio Network every Tuesday from 4 p.m. to 7 p.m. (Central Standard Time). The FIYAH SHOW provides a platform for humor, inspiration, and uplifting conversations. It's a space where the Word of God meets everyday life, with the motto: Where Real Talk Sparks Real Change and the slogan: Putting a Lil Heat to da Word on the Street.  Download the Anointed Radio Network App from the Google Play or Apple App Store to tune in live. ⁠www.anointedradio.com/⁠ Social Media: YouTube: @ibeYielded Instagram: @ibeYielded Facebook: @YieldedMedia Business Inquiries Email: ⁠yieldedmedia@gmail.com⁠ Watch us on Roku TV via the Anointed Radio Network Channel. Support this show: ⁠https://linktr.ee/yieldedmedia⁠ #FIYAHSHOW #RealTalkRealChange #PuttingALilHeat #AnointedRadio #ibeyielded #GospelEntertainment #ChristianTalkShow #HumorAndInspiration

Award-Winning Anointed Radio Network is a Las Vegas ChristianRadio Station provides a platform for all Christians to come and share about their businesses or talents. The Anointed Radio Motto is that (It is time to unite) every Wednesday 6 pm-7 pm (Pacific Standard Time (PST)Download the Anointed Radio Network App from the Google Play or Apple App Store.www.anointedradio.com/Social Media: Twitter:@lvanointedradio Instagram:@lvanointedradio Facebook:@ Anointed Radio Business inquires email: Lvanointedradio@gmail.com

Award-Winning Anointed Radio Network is a Las Vegas ChristianRadio Station provides a platform for all Christians to come and share about their businesses or talents. The Anointed Radio Motto is that (It is time to unite) every Wednesday 6 pm-7 pm (Pacific Standard Time (PST)Download the Anointed Radio Network App from the Google Play or Apple App Store.www.anointedradio.com/Social Media: Twitter:@lvanointedradio Instagram:@lvanointedradio Facebook:@ Anointed Radio Business inquires email: Lvanointedradio@gmail.com

The investment world is filled with overconfidence. We obsessively track our wins while conveniently forgetting our losses, leading most investors—even professionals—to achieve prediction accuracy barely above 50%. This sobering reality forms the foundation of a fascinating conversation about why predicting markets is so difficult and how diversification offers protection against our behavioral biases.When we zoom in too closely on market movements, every fluctuation appears significant, triggering emotional responses that frequently sabotage our long-term success. The natural instincts that serve us well in everyday life often lead to counterproductive investment behaviors—buying high and selling low in response to fear and greed. A risk parity framework offers an antidote to these tendencies by emphasizing balanced exposure across assets that respond differently to various economic conditions.True diversification extends far beyond traditional 60/40 portfolios, which typically show 98% correlation with equity markets. Instead, it requires thoughtful allocation across stocks, bonds, commodities, and inflation-protected securities, weighted according to their volatility characteristics. Historical data supports this approach: equities have experienced "lost decades" in two of the past five decades, while alternative assets like gold have delivered comparable long-term returns but performed best during equity's worst periods. This complementary performance pattern demonstrates why diversification across uncorrelated assets provides the only "free lunch" in investing.Today's environment of heightened uncertainty and inflation volatility makes diversified approaches more valuable than ever. While many portfolios have become increasingly concentrated in U.S. equities after years of outperformance, the coming decade may reward those who embrace a more balanced approach to navigating the unknowable future. Remember: investing isn't about predicting tomorrow perfectly—it's about building resilient portfolios that can thrive across diverse economic scenarios.Riddler Road Rally is not your average adventure. It's a live, citywide scavenger hunt on wheels, that will be the most fun you have this summer!Riddler Road Rally is hitting eleven cities across Utah and Idaho. Each rally brings new clues and its own vibe, with pre-rally parties, swag giveaways, and surprise diversions. Whether you rep your hometown or hit every stop on the Wasatch Tour to climb the 2025 leaderboard, the choice is yours.You and your team will race across t Sign up to The Lead-Lag Report on Substack and get 30% off the annual subscription today by visiting http://theleadlag.report/leadlaglive. Foodies unite…with HowUdish!It's social media with a secret sauce: FOOD! The world's first network for food enthusiasts. HowUdish connects foodies across the world!Share kitchen tips and recipe hacks. Discover hidden gem food joints and street food. Find foodies like you, connect, chat and organize meet-ups!HowUdish makes it simple to connect through food anywhere in the world.So, how do YOU dish? Download HowUdish on the Apple App Store today:

Make new friends but keep the old...the really old, sometimes entertaining your kids means getting to hangout with sexy firefighters, and Benny Blanco and Selena Gomez haven't started planning their wedding yet so we wanted to know who out there has a long a** engagement. Catch up on everything you missed from today's show on The Morning Mix Podcast!Listen to The Morning Mix weekdays from 5:30am - 10:00am on 101.9fm The Mix in Chicago or with the free Mix App available in the Apple App Store and Google Play.Follow The Mix: The MixstagramGet the Free MIX App: Stream The MixSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Nehemiah was God's chosen person and because of that he had a burden for God's work.  He earnestly prayed for God's people and God's place, and his prayer was answered.  As His children, we too need to be prayerful, specifically towards the church of Jesus Christ. VF-1990  Nehemiah 1 & 2 Watch, Listen and Learn 24x7 at PastorMelissaScott.com Pastor Melissa Scott teaches from Faith Center in Glendale. Call 1-800-338-3030 24x7 to leave a message for Pastor Scott. You may make reservations to attend a live service, leave a prayer request or make a commitment. Pastor Scott appreciates messages and reads them often during live broadcasts. Follow @Pastor_Scott on Twitter and visit her official Facebook page @Pastor.M.Scott. Download Pastor Scott's "Understand the Bible" app for iPhone, iPad and iPod at the Apple App Store and for Android devices in the Google Store. Pastor Scott can also be seen 24x7 on Roku and Amazon Fire on the "Understand the Bible?" channel. ©2025 Pastor Melissa Scott, Ph.D., All Rights Reserved

You love your spouse or partner. But is working with them a good idea? In this episode of the Best Practices Show, Kirk Behrendt brings back Dr. Charlie Ward, visiting faculty member at The Pankey Institute, along with his wife and fellow dentist, Dr. Melody Ward, to share the benefits and challenges of working together and their secrets for making it work. To learn how they've done it for over a decade, listen to Episode 915 of The Best Practices Show!Learn More About Dr. Charlie Ward & Dr. Melody Ward:Send Dr. Charlie Ward an email: charlie@bmoredentalarts.com Follow Dr. Charlie Ward on Instagram: https://www.instagram.com/drcwardddsWatch Dr. Charlie Ward's webinars: https://restorativenation.comFollow Dr. Melody Ward on Instagram: https://www.instagram.com/mwardperioLearn more about their practice: https://www.baltimoredentalarts.comMore Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast: https://podcasts.apple.com/us/podcast/the-best-practices-show-with-kirk-behrendt/id1223838218Episode Resources:Watch the video version of Episode 915: https://www.youtube.com/@actdental/videosMain Takeaways:Have the conversation about why you want to work together and your goals in doing so.Learn about each other's personalities to improve understanding and communication.Make the time to get away from your practice and your family with your spouse.Be intentional about your time off. Going to CE doesn't count as vacation!Set clear rules and boundaries so you limit bringing work back home.Check in regularly with your spouse. Things are always changing.Snippets:0:00 Introduction.2:13 Dr. Charlie Ward's background.3:46 Dr. Melody Ward's background.5:04 How they make it...

Every other week I'm republishing one of my most popular or impactful episodes and adding an update, new insight, or context that will help you benefit from it even more. This week I'm highlighting Episode #69, which is all about imposter syndrome. I've talked about imposter syndrome time and time again to different groups of nursing students and that's because almost every single person can relate. If you've ever said to yourself, "I don't belong here" or "They're going to find out I don't know what I'm talking about" then you may very well suffer from imposter syndrome. In this podcast episode, Nurse Mo talks about imposter syndrome, why it's so common in nursing students and why it has absolutely nothing to do with how amazing you actually are. ___________________ ⁠Full Transcript⁠ - Read the article and view references ⁠FREE CLASS⁠ - If all you've heard are nursing school horror stories, then you need this class! Join me in this on-demand session where I dispel all those nursing school myths and show you that YES...you can thrive in nursing school without it taking over your life! ⁠Crucial Concepts Bootcamp⁠ - Start nursing school ahead of the game, or reset after a difficult first semester with my nursing school prep course, Crucial Concepts Bootcamp. Learn key foundation concepts, organization and time management, dosage calculations, and so much more. ⁠20 Secrets of Successful Nursing Students⁠ – Learn key strategies that will help you be a successful nursing student with this FREE guide! ⁠Study Sesh⁠ - Change the way you study with this private podcast that includes dynamic audio formats that help you review and test your recall of important nursing concepts on-the-go. Free yourself from your desk with Study Sesh! ⁠Straight A Nursing App⁠ - Study on-the-go with the Straight A Nursing app! Review more than 5,000 flashcards covering a wide range of subjects including Fundamentals, Pediatrics, Med Surg, Mental Health, Maternal Newborn, and more! Available for free in the Apple App Store and Google Play Store.

The morning Mix is BACK baby and we are learning about all the rules you are breaking because it's summertime, you or a loved one have a dumb job title and we try to figure out what you do, and today's Thursday Threestyle may not be bussin' but it is BUZZIN'....and biting. Catch up on everything you missed from today's show on The Morning Mix Podcast!Listen to The Morning Mix weekdays from 5:30am - 10:00am on 101.9fm The Mix in Chicago or with the free Mix App available in the Apple App Store and Google Play.Follow The Mix: The MixstagramGet the Free MIX App: Stream The MixSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Confusion surrounding the emergence and development of Christianity has fueled a great deal of tension between Jews and Christians in our present time.  A deep dive into the book of Acts helps us to fill in the gaps and shed light on the early Christian church which in its genesis was made up of Jewish converts who came to view Christ as the Messiah. VF-2495 Watch, Listen and Learn 24x7 at PastorMelissaScott.com Pastor Melissa Scott teaches from Faith Center in Glendale. Call 1-800-338-3030 24x7 to leave a message for Pastor Scott. You may make reservations to attend a live service, leave a prayer request or make a commitment. Pastor Scott appreciates messages and reads them often during live broadcasts. Follow @Pastor_Scott on Twitter and visit her official Facebook page @Pastor.M.Scott. Download Pastor Scott's "Understand the Bible" app for iPhone, iPad and iPod at the Apple App Store and for Android devices in the Google Store. Pastor Scott can also be seen 24x7 on Roku and Amazon Fire on the "Understand the Bible?" channel. ©2025 Pastor Melissa Scott, Ph.D., All Rights Reserved

Have you ever felt lonely and unloved? Charles Weigle felt that way, too. When God reminded him how much he was loved, Charles wrote a hymn. Tune in today with Kyle and Brianna to discover the story behind this hymn. U-Nite TV Uniting kids with the God's Word in a fun, engaging way to help kids understand and apply biblical truths to their lives. Stream animated adventures, music videos, missionary stories, and more! Available on Android, iOS, Android TV, and Apple TV. https://www.cefonline.com/unitetv/ U-Nite Kids App Uniting kids in with God's Word to help them grow in their faith through personal devotions. Play adventures that teach truths from the Bible, complete daily devotions, earn achievements, memorize God's Word, and get answers to common biblical questions. Available on the Apple Appstore, Google Play, and the Amazon Appstore. https://www.cefonline.com/unitekids/ Copyright © 2025 Child Evangelism Fellowship Inc. All rights reserved. Scripture quotations are from the ESV® Bible (The Holy Bible, English Standard Version®), copyright© 2001 by Crossway, a publishing ministry of Good News Publishers. Used by permission. All rights reserved.

The Resurrection of Jesus Christ is the epicenter of Christianity. Jesus foretold of His Death and Resurrection on the 3rd day.  There are internal evidences that the New Testament writers were honest reporters of Christ's scourging and crucifixion, His burial, and His appearances after the Resurrection.  Because He is risen, we have the promise of life eternal. VF-2494 Watch, Listen and Learn 24x7 at PastorMelissaScott.com Pastor Melissa Scott teaches from Faith Center in Glendale. Call 1-800-338-3030 24x7 to leave a message for Pastor Scott. You may make reservations to attend a live service, leave a prayer request or make a commitment. Pastor Scott appreciates messages and reads them often during live broadcasts. Follow @Pastor_Scott on Twitter and visit her official Facebook page @Pastor.M.Scott. Download Pastor Scott's "Understand the Bible" app for iPhone, iPad and iPod at the Apple App Store and for Android devices in the Google Store. Pastor Scott can also be seen 24x7 on Roku and Amazon Fire on the "Understand the Bible?" channel. ©2025 Pastor Melissa Scott, Ph.D., All Rights Reserved

When leadership isn't aligned, it will lead to chaos. So, how do you prevent conflict and the day-to-day struggles? In this episode of Practical Solutions Day, Kirk Behrendt brings back Carlie Einarson, one of ACT's amazing coaches, with three keys to alignment and healthy partnerships. Misalignment is the root of all evil! To learn how to get in sync to gain trust and boost productivity, listen to Episode 914 of The Best Practices Show!Learn More About Carlie:Send Carlie an email: carlie@actdental.com Follow Carlie on ACT's Instagram: https://www.instagram.com/actdentalSend Courtney an email to learn more about ACT: courtney@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast: https://podcasts.apple.com/us/podcast/the-best-practices-show-with-kirk-behrendt/id1223838218Episode Resources:Watch the video version of Episode 914: https://www.youtube.com/@actdental/videosJoin ACT's BPA for the Strategic Vision Creator tool: https://join.actdental.com/users/sign_in?post_login_redirect=https%3A%2F%2Fjoin.actdental.com%2Fc%2Fpractice-coaching-tools%2Fstrategic-vision-creator-tool#emailRegister for ACT's To The Top Study Club (July 18th, 2025): https://www.eventbrite.com/e/climb-with-us-register-for-july-18-2025-ttt-study-club-tickets-1205460116659Register for ACT's To The Top Study Club (July 25, 2025): https://www.eventbrite.com/e/climb-with-us-register-for-july-25-2025-ttt-study-club-tickets-1205497959849Main...

If you're on the fence about whether or not you should be a Christian, this message gives you the tools to investigate and determine whether or not the Bible is authentic, valid and true. VF-2493 Watch, Listen and Learn 24x7 at PastorMelissaScott.com Pastor Melissa Scott teaches from Faith Center in Glendale. Call 1-800-338-3030 24x7 to leave a message for Pastor Scott. You may make reservations to attend a live service, leave a prayer request or make a commitment. Pastor Scott appreciates messages and reads them often during live broadcasts. Follow @Pastor_Scott on Twitter and visit her official Facebook page @Pastor.M.Scott. Download Pastor Scott's "Understand the Bible" app for iPhone, iPad and iPod at the Apple App Store and for Android devices in the Google Store. Pastor Scott can also be seen 24x7 on Roku and Amazon Fire on the "Understand the Bible?" channel. ©2025 Pastor Melissa Scott, Ph.D., All Rights Reserved

Understanding why Jesus had to die has many nuances that can be found throughout the Bible. The consequence for our fallen, sin-stained condition is death, but Jesus died as a substitute sacrifice in our place.  We escape the curse of the law through His finished work at the cross and the barrier between us and God is gone.  We are still sinners, but those who are in Christ will not receive God's wrath.  VF-2492 Watch, Listen and Learn 24x7 at PastorMelissaScott.com Pastor Melissa Scott teaches from Faith Center in Glendale. Call 1-800-338-3030 24x7 to leave a message for Pastor Scott. You may make reservations to attend a live service, leave a prayer request or make a commitment. Pastor Scott appreciates messages and reads them often during live broadcasts. Follow @Pastor_Scott on Twitter and visit her official Facebook page @Pastor.M.Scott. Download Pastor Scott's "Understand the Bible" app for iPhone, iPad and iPod at the Apple App Store and for Android devices in the Google Store. Pastor Scott can also be seen 24x7 on Roku and Amazon Fire on the "Understand the Bible?" channel. ©2025 Pastor Melissa Scott, Ph.D., All Rights Reserved

Zohran Mamdani's far-left mayoral victory in New York could signal a takeover of the Democratic Party—and a warning for November. Political analyst and native New Yorker Ryan Girdusky breaks it all down. Get the facts first with Morning Wire. - - - Today's Sponsors: EarnIn - Type in "Morning Wire" under PODCAST when you sign up for EarnIn today by downloading in the Google Play or Apple App Store. Jeremy's Razors - Get 25% off Jeremy's Razors for a limited time: https://www.jeremysrazors.com/?utm_campaign=Independence&utm_content=20250624&utm_source=pod - - - Privacy Policy: https://www.dailywire.com/privacy

Fourth of July weekend is coming up and Chris is dealt a difficult hand for this week's Thursday Threestyle, we made listeners do impressions of their favorite fireworks, and we truck around and find out why you wouldn't date someone in your career. Catch up on everything you missed from today's show on The Morning Mix Podcast!Listen to The Morning Mix weekdays from 5:30am - 10:00am on 101.9fm The Mix in Chicago or with the free Mix App available in the Apple App Store and Google Play.Follow The Mix: The MixstagramGet the Free MIX App: Stream The MixSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The DOJ cracks down on “sanctuary city” Los Angeles, Trump lambasts two American institutions, and Democrats dig in their heels to slow the Big Beautiful Bill. Get the facts first with Morning Wire. - - - Today's Sponsors: EarnIn - Type in Morning Wire under PODCAST when you sign up for EarnIn today by downloading in the Google Play or Apple App Store. Pockethose - Text MORNINGWIRE to 64000 to get a FREE pocket pivot and their 10-pattern sprayer with the purchase of ANY size Copper Head hose. Message and data rates may apply. - - - Privacy Policy: https://www.dailywire.com/privacy

New intelligence reveals the extent of the damage to Iran's nuclear facilities, RFK yanks funding from a global vaccine group, and New York City reels as a socialist claims victory in the Democratic primary for mayor. Get the facts first with Morning Wire. - - - Today's Sponsors: EarnIn - Type in Morning Wire under PODCAST when you sign up for EarnIn today by downloading in the Google Play or Apple App Store. Mosh - Head to https://moshlife.com/MORNINGWIRE to save 20% off plus FREE shipping on the Best Sellers Trial Pack. Shopify - Go to https://Shopify.com/morningwire to sign up for your $1 per month trial period and upgrade your selling today. - - - Privacy Policy: https://www.dailywire.com/privacy